1. Signaling Pathways
  2. MAPK/ERK Pathway
  3. MEK
  4. MEK2 Isoform

MEK2

 

MEK2 Related Products (17):

Cat. No. Product Name Effect Purity
  • HY-10999
    Trametinib
    Inhibitor 99.92%
    Trametinib (GSK1120212; JTP-74057) is an orally active MEK inhibitor that inhibits MEK1 and MEK2 with IC50s of about 2 nM.
  • HY-12028
    PD98059
    Inhibitor 99.94%
    PD98059 is a potent and selective MEK inhibitor with an IC50 of 5 µM.
  • HY-12031
    U0126-EtOH
    Inhibitor 99.41%
    U0126 (U0126-EtOH) is a potent, non-ATP competitive and selective MEK1 and MEK2 inhibitor, with IC50s of 72 nM and 58 nM, respectively.
  • HY-10254
    Mirdametinib
    Inhibitor 99.95%
    Mirdametinib (PD0325901) is an orally active, selective and non-ATP-competitive MEK inhibitor with an IC50 of 0.33 nM.
  • HY-50706
    Selumetinib
    Inhibitor 99.87%
    Selumetinib (AZD6244) is selective, non-ATP-competitive oral MEK1/2 inhibitor, with an IC50 of 14 nM for MEK1.
  • HY-10999A
    Trametinib (DMSO solvate)
    Inhibitor 99.74%
    Trametinib (DMSO solvate) (GSK-1120212 (DMSO solvate);JTP-74057 (DMSO solvate)) is an orally active MEK inhibitor that inhibits MEK1 and MEK2 with IC50s of about 2 nM.
  • HY-12042
    Pimasertib
    Inhibitor 99.70%
    Pimasertib (AS703026) is a highly selective, ATP non-competitive allosteric orally available MEK1/2 inhibitor.
  • HY-14691
    Refametinib
    Inhibitor 99.82%
    Refametinib (BAY 869766; RDEA119) is an orally available, potent, non-ATP-competitive, selective, allosteric MEK1/MEK2 inhibitor with IC50s of 19 nM and 47 nM, respectively.
  • HY-18955
    BI-847325
    Inhibitor 98.66%
    BI-847325 is an ATP competitive dual inhibitor of MEK and aurora kinases (AK) with IC50 values of 4 and 15 nM for human MEK2 and AK-C, respectively.
  • HY-15437
    SL327
    Inhibitor ≥98.0%
    SL327 inhibits MEK1 and MEK2, with IC50 values of 180 nM and 220 nM, respectively.
  • HY-12058
    AZD8330
    Inhibitor 99.14%
    AZD8330 (ARRY-424704) is a potent, uncompetitive MEK1/MEK2 inhibitor, with an IC50 of 7 nM.
  • HY-130602
    MS432
    Inhibitor 98.20%
    MS432 is a first-in-class and highly selective PD0325901-based von Hippel-Lindau-recruiting PROTAC degrader for MEK1 and MEK2.
  • HY-14719
    RO4987655
    Inhibitor 99.26%
    RO4987655 is an orally active and highly selective MEK inhibitor with an IC50 of 5.2 nM for inhibition of MEK1/MEK2.
  • HY-12062
    PD318088
    Inhibitor 99.88%
    PD318088 is a potent, allosteric and non-ATP competitive MEK1/2 inhibitor, an analog of PD184352 (HY-50295).
  • HY-107417
    Hypothemycin
    Inhibitor ≥98.0%
    Hypothemycin, a fungal polyketide, is a multikinase inhibitor with Kis of 10/70 nM, 17/38 nM, 90 nM, 900 nM/1.5 μM, and 8.4/2.4 μM for VEGFR2/VEGFR1, MEK1/MEK2, FLT-3, PDGFRβ/PDGFRα, and ERK1/ERK2, respectively.
  • HY-131295
    PD0325901-O-C2-dioxolane
    Inhibitor 98.76%
    PD0325901-O-C2-dioxolane has main portion of MEK inhibitor PD0325901.
  • HY-12031A
    U0126
    Inhibitor
    U0126 is a potent, non-ATP competitive and selective MEK1 and MEK2 inhibitor, with IC50s of 72 nM and 58 nM, respectively.